
|Articles|April 20, 2017
Study Reveals Treatment Strategy for Triple-Negative Breast Cancer
Author(s)Mateusz Opyrchal, MD, PhD
Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.
Advertisement
Mateusz Opyrchal, MD, PhD, of Roswell Park Cancer Institute in Buffalo, talks about a novel interaction between AURKA and the MAPK pathway in wild-type BRAF breast cancer cells and the cytotoxic effect of AURKA- and MEK1/2-specific inhibitors against estrogen-positive and triple-negative breast cancer cells.
Dr. Opyrchal gave a
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
CAR-T Moves to the Front Line: Rethinking the Multiple Myeloma Sequence
2
Anbenitamab Injection Combo Meets pCR End Point in HER2+ Breast Cancer
3
Urine-Based Biopsy Shows 97.8% Sensitivity in Prostate Cancer Detection
4
FDA Approves Brexucabtagene Autoleucel in Adult R/R MCL
5























































